Resource Library

Topics

Filters

Resource Library

New to the Resource Library?

Learn how to navigate, search, and use our resources effectively.

How to use the Library

Alterations in BNST Intrinsic Functional Connectivity in Early Abstinence from Alcohol Use Disorder

The article finds that changes in brain regions, particularly the BNST network, contribute to relapse in alcohol use disorder. Understanding these changes could help identify individuals at risk and guide new treatments.

(2023)

Characteristics of Stress Sensitivity in Heroin Use Disorder Patients during Their Opioid Agonist Treatment

Opioid use disorder is a chronic brain disease causing lasting brain changes. This article suggests addiction has a specific psychopathology, distinct from other mental health conditions, that can inform personalized treatment approaches.

stress sensitivityheroin addictionOATheroin addiction historypsychopathologybehavioural covariates of heroincocaine and cannabis cravingsubjective wellness
(2023)

Contextual Processing and its Alterations in Patients with Addictive Disorders

Opioid addiction is a major public health issue linked to impaired contextual processing, which impacts decision-making. Researchers are studying how this impairment affects individuals with opioid, alcohol, or both dependencies.

heroinalcoholsucroserewardaversionmotivationbeautymonetaryfree willreinforcement
(2023)

Crosstalk between Mu-Opioid receptors and neuroinflammation: Consequences for drug addiction and pain

This article explains that Mu-Opioid Receptors (MORs) are critical for processes like pain and reward. Dysregulation can lead to disorders like addiction and pain. MORs also influence neuroinflammation, which could lead to new treatments.

Opioid signalingNeuroimmunityReinforcementNociception
(2023)

Dysregulation of the Endogenous Cannabinoid System Following Opioid Exposure

This review summarizes evidence for endocannabinoid system (ECS) dysregulation in opioid use disorder (OUD). It explores how the ECS, a stress regulatory system, could be a new target for OUD treatments.

Opioid Use DisorderOpioidsEndocannabinoidsEndocannabinoid systemPharmacologic ActionsAnimal ModelsAddiction
(2023)

GABAergic signaling in alcohol use disorder and withdrawal: Pathological involvement and therapeutic potential

Alcohol use disorders affect many people globally and are linked to numerous health issues. While ethanol impacts various brain pathways, a key focus is its effect on the brain's inhibitory GABA pathway.

alcohol use disordersclinical trialsGABAintegrative approachinterventionspharmacotherapytranslationalunmet need
(2023)

Investigating Behavioral and Neuronal Changes in Adolescent Mice Following Prenatal Exposure to Electronic Cigarette (E-Cigarette) Vapor Containing Nicotine

E-cigarette exposure during the first trimester of mouse pregnancy led to adolescent offspring having altered anxiety, recognition memory, and increased nicotine preference. These changes suggest a link to psychiatric disorder phenotypes.

electronic cigarettesnicotine addictionadolescence
(2023)

Neuropsychological functioning of patients with major depression or bipolar disorder comorbid to substance use disorders: A systematic review

The co-occurrence of substance use disorders and mental health conditions, called dual disorders, is common and linked to worse health outcomes. Major depression and bipolar disorder are the most frequently reported co-occurring conditions.

Bipolar disorderCognitionDepressive symptomsDual disorderMajor depression disorderSubstance use disorder
(2023)

Default Mode Network Modulation by Psychedelics: A Systematic Review

Psychedelics, known as "mind-manifesting" agents, may alter consciousness by affecting the brain's Default Mode Network (DMN). These effects show promise for treating various neuropsychiatric conditions.

psychedelicspsilocybinLSDayahuascaconnectivityDMN
(2023)

Psychedelics reopen the social reward learning critical period

Research shows that various psychedelics can reopen a "critical period" in the brain, enhancing social reward learning in adulthood. This suggests a common mechanism that may contribute to their therapeutic potential.

PsychedelicsCritical period reopeningSocial reward learningMDMAMetaplasticityExtracellular MatrixTherapeutic effectsPTSDDepressionLSD
(2023)

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

This study explored challenging psychedelic experiences in a representative US adult sample. It examined how psychological traits, medication use, and environment relate to these experiences.

PsychedelicsPsilocybinLSDAdverseRiskChallengingCEQ
(2023)

Case analysis of long-term negative psychological responses to psychedelics

This study focuses exclusively on negative psychological responses to psychedelics that last longer than 72 hours. It aims to understand why these long-term negative mental health issues occur, given growing general use.

PsychedelicsNegative psychological responsesMental healthRisk factorsHPPDPsychotic symptomsSet and settingChallenging experiencesTherapeutic potentialDrug policy
(2023)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Researchers discovered that psychedelics like LSD and psilocybin directly bind to a protein called TrkB with high affinity.

PsychedelicsTrkBBDNFneuroplasticityantidepressantsLSDpsilocybin5-HT2A receptorhallucinogenic effectsplasticity-promoting effects
(2023)

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

This study found that certain compounds, including psychedelics, can rapidly promote new brain cell growth and have antidepressant-like effects. This growth appears linked to their ability to activate serotonin receptors inside cells.

NeuroplasticityPsychedelics5-HT2A receptorsSerotoninDendritic spine densityLipophilicityIntracellular receptorsMembrane permeabilityGolgi apparatusAntidepressant
(2023)

Psychedelics: Threshold of a Therapeutic Revolution

This issue updates research on psychedelic drugs, showing remarkable progress in basic and clinical studies since 2018. It details current policies, ethics, and legal considerations for their potential use as mainstream therapies.

PsilocybinMDMApsychedelicsclinical trialsmental healthdrug developmentFDA approvalPTSDdepression
(2023)